. The widespread biological significance of serine hydrolases has motivated many academic and industrial groups to develop inhibitors for enzymes from this class, both for use as chemical probes to study enzyme function and as potentially new therapeutic agents. Four general strategies have been successfully used: mining natural products (proteins, polysaccharides and small molecules); converting endogenous substrates into inhibitors; screening large compound libraries and optimizing lead scaffolds; and tailoring compounds containing mechanism-based electrophiles -including carbamates 12, 13 , ureas 14, 15 , activated ketones 16 as well as lactones and lactams 17, 18 -that covalently react with the serine nucleophile in the active site.
Although the last approach overlaps with the other strategies -for example, electrophiles are intrinsic in some natural product scaffolds 19, 20 and have been extensively used as 'warheads' on enzyme substrates and/or products to convert them into inhibitors 21, 22 -broadly screening 'hydrolase-directed' electrophile libraries against serine hydrolases has emerged as a particularly fruitful independent approach for the identification of serine hydrolase inhibitors 12, 15 . Together, these efforts have yielded an array of pharmacological tools, including proteins, peptides, polysaccharides and small molecules, that inhibit serine hydrolases with good selectivity, and several of these agents have been approved for clinical use to treat diseases such as type 2 diabetes, obesity, blood-clotting disorders and Alzheimer's disease, as well as bacterial and viral infections (TABLE 1; Supplementary information S1 (table)) .
Despite these advances, the vast majority of eukaryotic and prokaryotic serine hydrolases lack selective, in vivo-active inhibitors. Even in cases in which inhibitors have been identified for certain human serine hydrolases, many of these lack comprehensive selectivity profiles and evaluations of in vivo efficacy. Furthermore, many serine hydrolases, including some that have been genetically linked to human diseases 1 , remain uncharacterized with respect to their physiological substrates and functions. In this Review, we survey the current Nature Reviews | Drug Discovery 
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pharmacological toolkit and therapeutic potential for human serine hydrolases, giving special attention to modern chemoproteomic methods that have quickened the pace of inhibitor discovery and optimization. We also discuss the challenges that must be overcome to create selective inhibitors for the vast majority ofif not all -mammalian serine hydrolases, and highlight how these challenges are being met by advances in screening and the development of classes of compounds that have a preferential capacity to inactivate serine hydrolases.
The human serine hydrolases
There are ~240 human serine hydrolases, which can be divided into two subgroups of nearly equal size -the serine proteases (~125 members) and the metabolic serine hydrolases (~115 members) 7 (table) ). The vast majority of serine proteases, which primarily cleave peptide bonds in proteins, have chymotrypsin-like or subtilisin-like folds (FIG. 2) and have a serine nucleophile that is activated by participating in a catalytic triad with conserved histidine and aspartic acid residues 23 . Serine proteases typically exist as inactive precursors (that is, zymogens), which are activated by limited proteolysis following specific biological stimuli and are subsequently inactivated by endogenous protein inhibitors 23, 24 . These enzymes include the well-studied digestive protease trypsin and the critical blood-clotting mediators thrombin and activated factor Xa.
The metabolic serine hydrolases (FIG. 2) are composed of a range of lipases, peptidases, esterases, thioesterases and amidases that hydrolyse small molecules, peptides or post-translational ester (or thioester) protein modifications 7 . Consistent with their diverse substrate repertoire, the metabolic serine hydrolases represent a much more structurally diverse group of enzymes than the serine proteases (FIG. 2) . Despite this diversity, most metabolic serine hydrolases -including both characterized and uncharacterized enzymes -possess clear orthologues between rodents and humans that share >80% sequence identity 7 (the main exception is the carboxylesterases, which are greatly expanded in rodents compared to humans) 25 . The majority (>60%) of metabolic serine hydrolases have an α/β-hydrolase fold and a Ser-His-Asp catalytic triad but this subfamily also includes structurally and mechanistically distinct enzyme classes such as the patatin domain-containing lipases 26 and the amidase signature enzymes 27, 28 , which use Ser-Asp dyads and SerSer-Lys triads for catalysis, respectively. Although several members of the metabolic serine hydrolase family have been extensively characterized, including acetylcholinesterase (AChE), fatty acid amide hydrolase (FAAH) and dipeptidyl peptidase 4 (DPP4), the majority are still not annotated with respect to their physiological substrates and functions 7 .
Clinically approved inhibitors
Small-molecule inhibitors have been clinically approved for six distinct human serine hydrolase targets, four of which are described below (TABLE 1) . As several of these compounds are not selective for a single enzyme, and at least one, orlistat (Xenical/Alli; Roche/GlaxosmithKline), is thought to derive its therapeutic benefit by inhibiting several related enzymes 29 , the actual number of human serine hydrolases targeted by commercial drugs is likely to be higher than six. Interestingly, despite the pharmaceutical industry's perceived aversion to developing therapeutics that form covalent bonds with protein targets 30 , five of these drugs -rivastigmine (Exelon; Novartis) 31 , saxagliptin (Onglyza; Bristol-Myers Squibb) 32 , vildagliptin (Zomelis; Novartis) 33 , orlistat 34 and sivelestat (Elaspol; Ono Pharmaceutical) 35, 36 -contain electrophilic chemical groups that interact covalently with the serine nucleophile in the active site of their targets.
Additional examples of electrophilic drugs that target serine hydrolases include the β-lactam antibiotics 37 , which inhibit bacterial transpeptidase and β-lactamase enzymes, and the recently approved hepatitis C virus (HCV) drugs boceprevir (Victrelis; Merck) and telaprevir (Incivek; Vertex Pharmaceuticals) 38 , which are α-keto amides that inhibit the HCV NS3 protease. A detailed discussion of bacterial and viral hydrolases is beyond the scope of this Review, but they have been extensively reviewed in the literature (reviewed in  further information is also provided in Supplementary information S1 (table) ). In addition to small-molecule inhibitors, several large biomolecules and their derivatives (proteins, peptides and polysaccharides) that target serine hydrolases, such as thrombin, are either in clinical development or have been approved for clinical use 42 . However, this Review focuses specifically on small-molecule inhibitors of human serine hydrolases.
Inhibitors of serine proteases involved in coagulation.
Venous and arterial thromboembolic diseases, which are characterized by the occlusion of blood vessels by thrombi, are a major cause of morbidity and mortality worldwide 42 . Several serine proteases have central roles in the blood coagulation pathway, in which the sequential activation of protease zymogens results in the rapid formation of insoluble fibrin blood clots 2, 43 , and these enzymes have long been the main targets of anticoagulant drug development efforts. For the past 50 years, heparins and vitamin K antagonists (for example, warfarin), both of which indirectly inactivate several proteases in the coagulation cascade, have been the two major anticoagulant drug classes. However, the use of these agents is associated with important clinical drawbacks: heparins require parenteral administration owing to their large size, and warfarin (although orally available) has a narrow therapeutic window, is associated with many food-drug interactions and requires frequent monitoring 42 . More recent research efforts have focused on the development of selective and orally available small molecules that directly block one of two key coagulation proteases: thrombin (also known as factor IIa) and activated factor Xa.
Thrombin, the final protease in the coagulation cascade, cleaves fibrinogen into fibrin, potently activates platelets and indirectly activates itself through a feedback loop 44 . Injectable direct thrombin inhibitors have been available for many years; the leech salivary peptide hirudin 45 , the hirudin derivative bivalirudin 46 and the small molecule argatroban 47 (TABLE 1) are all clinically approved direct thrombin inhibitor anticoagulants 48 . The first orally available small-molecule direct thrombin inhibitor, ximelagatran (Exanta; AstraZeneca), was developed from a peptide scaffold that mimicked the thrombin substrate fibrinogen 44 . Ximelagatran, however, exhibited serious liver toxicity; consequently, it was not approved in the United States and was withdrawn from the European market in 2006 (REF. 49 ).
The next attempt to develop an orally available direct thrombin inhibitor originated from an X-ray crystal structure of the peptide-like, benzamidine-based inhibitor NAPAP in complex with bovine thrombin 50 . Replacement of the central NAPAP glycine residue with a more rigid isostere and its subsequent optimization resulted in the development of the reversible inhibitor dabigatran, which exhibited excellent anticoagulant activity in human blood LO NP 1 with good selectivity for thrombin over related serine proteases 51 . However, dabigatran was not orally bioavailable, which was likely to be due to a highly basic amidine residue that was included to mimic the fibrinogen substrate. To achieve oral bioavailability, dabigatran was masked as a double prodrug (TABLE 1), dabigatran etexilate (Pradaxa; Boehringer Ingelheim), which is hydrolysed to release dabigatran in vivo 52 . Importantly, dabigatran etexilate did not show any evidence of liver toxicity 53 , and has recently gained regulatory approval worldwide. The remaining enzymes are serine proteases, with chymotrypsin-like enzymes depicted using grey lines, subtilisin-like enzymes depicted using red lines, and other smaller serine protease classes depicted using green lines. The dendrogram was constructed by performing a sequence alignment anchored around the catalytic serine nucleophile of each enzyme using the DIALIGN algorithm 217 . All the serine hydrolases included in the dendrogram are listed in Supplementary information S2 (table) .
Factor Xa, the other major protease target for the development of anticoagulants, cleaves prothrombin into active thrombin 54 . Potent parenteral factor Xa inhibitors have been available for decades, including the polypeptides antistasin 55, 56 and the tick anticoagulant peptide 57 . Together with the more recently introduced pentasaccharide fondaparinux (Arixtra; GlaxoSmithKline) 58 , which is an analogue of the heparin core that selectively inhibits factor Xa but not thrombin, these agents were crucial in elucidating the role of factor Xa in thrombosis and validating selective factor Xa inhibition as a therapeutic strategy 59 . Initial smallmolecule factor Xa inhibitors all contained amidine residues that served as prothrombin mimetics 60, 61 . As was observed with dabigatran, this highly basic group -although crucial for potency -contributed to poor oral bioavailability 62, 63 . Bayer opted instead to screen a large library of (~200,000) compounds to identify a novel inhibitor scaffold 64 . From a lead with modest micromolar potency and structure-activity knowledge emanating from previous efforts, this team developed the highly potent, reversible factor Xa inhibitor rivaroxaban (Xarelto; Bayer) 59, 64 . In 2008 rivaroxaban became the first selective small-molecule inhibitor of factor Xa to be approved for clinical use 59 . Several additional smallmolecule inhibitors of both thrombin and factor Xa are currently in clinical development (reviewed in REF. 65 ).
AChE inhibitors to treat dementia associated with
Alzheimer's disease. AChE is a metabolic serine hydrolase that cleaves and inactivates the neurotransmitter acetylcholine 66 . More than 30 years ago, a decrease in cholinergic signalling was first observed in patients with Alzheimer's disease [67] [68] [69] , leading to the hypothesis that a loss in cholinergic neurotransmission contributed to the decline in cognitive function in these patients 70 . Consequently, it was proposed that increasing acetylcholine levels by inhibiting AChE could alleviate symptoms of this disease. This premise has been validated clinically, and three AChE inhibitors are currently used for the treatment of dementia associated with Alzheimer's disease (TABLE 1) . A fourth inhibitor, tacrine (Cognex; Shionogi), is approved but not recommended for use owing to its poor bioavailability and toxicity 71 . The successful use of these drugs depends on a graduated dosing regimen that avoids overt cholinergic toxicity 72 , such as that observed with large doses of organophosphorus nerve agents and insecticides that potently but non-selectively inhibit AChE 73 . The three AChE inhibitors in clinical use have notably different origins. Only one of these compounds, donepezil (Aricept; Eisai), is entirely synthetic -a result of the derivatization of a scaffold identified from compound screening 74 . Donepezil reversibly inhibits AChE, and out of all the approved inhibitors it has the highest selectivity (>1,000-fold) for AChE over the related serine hydrolase butyrylcholinesterase (BChE) 75, 76 . Galantamine (Razadyne; Johnson & Johnson/Janssen) is a natural product alkaloid that was first isolated in 1952 from the bulbs of the Caucasian snowdrop Galanthus woronowii 77 . Like donepezil, galantamine is a reversible inhibitor but has a more modest (50-fold) selectivity for AChE over BChE 78, 79 . The third approved compound, rivastigmine, is an optimized version of physostigmine, a natural product alkaloid with cholinergic activity 80 , with improved selectivity for the brain isoform of AChE over peripheral AChE and BChE isoforms 81 . Rivastigmine, like physostigmine, contains an aryl carbamate group that acts as a slowly turned over AChE substrate, effectively leading to the irreversible inactivation of the enzyme through carbamylation of its serine nucleophile 31 . Following on the success of rivastigmine, carbamates have emerged as a versatile chemotype for serine hydrolase inhibitors, as embedding this tempered reactive group into various structural scaffolds has led to the generation of selective inhibitors for several serine hydrolases 12, 82, 83 , as described below.
DPP4 inhibitors for the treatment of type 2 diabetes.
DPP4 is a serine peptidase that cleaves amino-terminal dipeptides from various polypeptides that contain a proline or alanine residue at the penultimate position 84 . The incretins glucagon-like peptide 1 and gastric inhibitory polypeptide, which are released from the gut after food intake to promote insulin secretion and improve pancreatic β-cell function, are prominent among the substrates of DPP4 21 . Appropriately positioned nitrile groups, particularly those that form covalent reversible bonds with the serine nucleophile of DPP4 to result in high-affinity binding 32, 93, 94 , led to the generation of selective and orally bioavailable compounds. These lead compounds were ultimately optimized to produce vildagliptin 33, 95 and saxagliptin 96, 97 . By contrast, sitagliptin 98 (Januvia; Merck) and linagliptin 99 (Tradjenta; Boehringer Ingelheim) were both optimized from novel structures -a β-amino acid scaffold 100 and a xanthene-based scaffold 99 , respectively -that were identified by screening compound libraries. Alogliptin emerged from medicinal chemistry efforts around a quinazolinone scaffold that was predicted to inhibit the active site of DPP4 by structure-based computational design 91 . Sitagliptin, linagliptin and alogliptin inhibit DPP4 through non-covalent, reversible mechanisms.
Emerging therapeutic targets
Many additional members of the serine hydrolase class have been implicated in diseases, and inhibitors for several of these targets are in clinical development (TABLE 2) . For example, FAAH inactivates a large class of amidated lipid transmitters, including the endogenous cannabinoid anandamide 101 . Genetic deletion or chemical inactivation of FAAH in rodents increases the levels of anandamide and related fatty acid amides, resulting in analgesia, anti-inflammatory effects, anxiolysis and antidepressant effects without causing the psychotropic side effects typically observed with direct cannabinoid receptor 1 (CB1) agonists 82, 102, 103 . For example, the α-keto heterocycle FAAH inhibitor OL-135 (TABLE 2) has demonstrated efficacy in several assays of pain sensation in rodents 104 , and the carbamate FAAH inhibitor URB597 (TABLE 2) reduces neuropathic pain in mice 105 and increases anandamide signalling in monkeys without inducing drug-seeking behaviour 106 . High-throughput screening of Pfizer's chemical library has uncovered a novel urea-containing FAAH inhibitor, which irreversibly inactivates the enzyme by covalently modifying the serine residue in the active site of FAAH 107 . The subsequent optimization of this scaffold resulted in the discovery of PF-04457845 (REFS 14,108) (TABLE 2), a urea with exceptional selectivity for FAAH over other serine hydrolases and excellent pharmacokinetic properties in rats and dogs. In a rat model of inflammatory pain, the oral administration of PF-04457845 (at a dose of 0.1 mg per kg) exhibited similar antihyperalgesic effects to naproxen administration (at a dose of 10 mg per kg), and PF-04457845 has since entered clinical trials. In addition to Pfizer, other companies including Sanofi, Merck and Infinity have launched FAAH inhibitor discovery programmes based on carbamates, substituted imidazoles and arylboronic acids, respectively 109 . Another example of an emerging drug target in the serine hydrolase class is the calcium-independent lowdensity lipoprotein (LDL)-associated phospholipase A2 (LDL-PLA2; also known as PLA2G7), which is principally secreted by leukocytes and associated with circulating LDL 110 . Elevated levels of PLA2G7 were discovered to strongly correlate with an increased risk of coronary heart disease, suggesting a potential role for this enzyme in atherogenesis 111 . PLA2G7 can hydrolyse polar phospholipids in oxidized LDL to generate two key pro-inflammatory mediators: lysophosphatidylcholine and oxidized non-esterified fatty acids 112, 113 . Lysophosphatidylcholine and oxidized non-esterified fatty acids have been implicated in the development of atherosclerosis through several mechanisms, including the homing of inflammatory cells and the induction of apoptosis 110 .
To investigate the biology and therapeutic potential of PLA2G7, GlaxoSmithKline optimized a selective picomolar inhibitor, darapladib 114 (TABLE 2) , from an initial micromolar high-throughput screening hit 115 . Darapladib blocked the production of lysophosphatidylcholine and non-esterified fatty acids in oxidized LDL 113 and significantly decreased the development of coronary atherosclerotic plaques in a diabetic and hyperchloesterolaemic swine model through an anti-inflammatory cholesterolindependent mechanism 116 . Darapladib is currently being evaluated in Phase III clinical trials.
Additional preliminary studies using knockout models, lead chemical inhibitors, as well as protein and gene expression profiling have highlighted the potential therapeutic importance of other serine hydrolases. For example, mice lacking prolylcarboxypeptidase (PRCP) -which cleaves carboxy-terminal amino acids after proline in bioactive peptides such as angiotensin II and III 117 -have a reduced body weight, food intake and fat mass, designating PRCP as a potential target for obesity 118 . Merck has reported initial attempts to develop PRCP inhibitors 119, 120 , the first of which, compound 8o (TABLE 2) , reversibly blocked PRCP activity with nanomolar potency and showed high selectivity over a panel of related serine peptidases 119 . Encouragingly, compound 8o reduced food intake, body weight and fat mass in wild-type mice to a greater extent than ablation in Prcp -/-mice. However, a recently reported second-generation PRCP inhibitor reduced body weight and food intake similarly in both wild-type and Prcp -/-mice 120 , indicating that the effects of the inhibitor, at least in this case, were independent of PRCP activity. The authors speculate that compound 8o may achieve higher levels of peripheral and/or central PRCP engagement than the secondgeneration compound, and are currently pursuing more structurally diverse inhibitors with improved bioavailability to further evaluate this premise.
Through studies in knockout mice three serine triglyceride hydrolases, carboxylesterase 1 (CES1; also known as TGH), adipose triglyceride lipase (ATGL) and endothelial lipase (LIPG), have been implicated as possible therapeutic targets for hypertriglyceridaemia, cancer-associated cachexia and cardiovascular disease, respectively. CES1 (referred to as CES3 in mice) can cleave triglyceride stores in hepatocytes, which, after lipolysis, can serve as substrates for the assembly of apolipoprotein B (APOB)-containing very-low-density lipoprotein particles [121] [122] [123] .
Ces3
-/-mice have significantly decreased plasma triacylglycerol and APOB levels, which are accompanied by improved insulin sensitivity and glucose tolerance 124 . GlaxoSmithKline has developed the CES1 inhibitor GR148672X 125 (TABLE 2) , but the selectivity, bioavailability and molecular interactions of this compound with CES1 have not been disclosed.
ATGL, which can also mediate the lipolysis of stored triglycerides in adipocytes and other tissues 126 , was recently evaluated for its role in an animal model of cancer-associated cachexia 127 . In this model, Atgl -/-mice resisted the loss of white adipose tissue and muscle mass observed in wild-type mice, suggesting that ATGL inhibition could slow or stop the progression of cancerassociated cachexia. To our knowledge, ATGL inhibitors have not yet been reported.
LIPG is an extracellular triglyceride lipase that also possesses substantial phospholipase activity 128 . Lipg -/-mice have increased high-density lipoprotein (HDL) levels compared to wild-type mice 129, 130 , whereas transgenic mice in which LIPG is overexpressed exhibit substantially reduced HDL levels 130 . As HDL levels are inversely correlated with risk of cardiovascular disease, these genetic models suggest that LIPG is a potential therapeutic target for this indication. GlaxoSmithKline has reported initial sulfonylfuran urea-based LIPG inhibitors (TABLE 2) , but these compounds also inhibit the related enzyme lipoprotein lipase and have not yet been evaluated in vivo 131 . Another potential drug target is prolyl endopeptidase (PREP; also known as prolyl oligopeptidase). PREP is a post-proline cleaving enzyme that is highly expressed in the brain, kidney, muscle and testis 132 , and can degrade various neuroactive peptides, including arginine vasopressininduced protein, substance P and thyrotropin-releasing hormone, among others 133 . As several of these substrates are involved in learning and memory, the inhibition of PREP has been suggested as a strategy for the treatment of cognitive defects associated with Alzheimer's disease, Parkinson's disease and ageing 134 . Most of the PREP inhibitor discovery efforts have been centred on the modification of Z-prolyl-prolinal, a peptide-based transitionstate analogue that competitively inhibits PREP 135 . Two compounds that emerged from this approach, JTP-4819 (REF. 136 ) and S-17092 (REF. 137) (TABLE 2), inhibit PREP selectively over related peptidases and elevate the levels of several PREP peptide substrates in the brains of compound treated-animals 136, [138] [139] [140] . Encouragingly, the inhibition of PREP has been shown to improve cognitive function in ageing rats 141 and in a chemically induced model of early parkinsonism in monkeys 142 . In preliminary studies in humans, S-17092 elicited improvements in a delayed memory task and in mood stabilization 143, 144 . Current studies that are focused on the continued development of inhibitors with improved bioavailability and potency, combined with detailed mechanistic studies to understand the cognition-enhancing effects of these compounds on a molecular level, should clarify the therapeutic potential of this target 145 . Several serine hydrolases, such as fatty acid synthase 6 , protein phosphatase methylesterase 1 (PPME1) 146 , urokinase-type plasminogen activator and tissue-type plasminogen activator 147 , have also been implicated in cancer 148 . Fibroblast activation protein (FAP; also known as seprase), the serine peptidase that is most homologous to DPP4 (FIG. 2) , is highly expressed by stromal fibroblasts in most epithelial cancers, and is therefore especially intriguing among potential cancer targets [149] [150] [151] . Transfection of FAP in cancer cells promotes tumour growth in animals 152 . The non-selective dipeptide boronic acid FAP inhibitor PT-100 (TABLE 2) (talabostat; Point Therapeutics) slowed tumour growth in mice, but its lack of specificity precludes the elucidation of the precise role of FAP inhibition in this model 153, 154 . A study has demonstrated that removing the FAP-positive subpopulation of tumour stromal cells arrests the growth of solid tumours by inducing an immune response 155 . The pursuit of selective FAP inhibitors should further elucidate the role of this enzyme in tumorigenesis 156, 157 . Activity-based protein profiling for target discovery. As noted above, many serine hydrolases are regulated by post-translational mechanisms, which means that changes in their activity may not correlate well with their expression levels as measured by conventional proteomic [158] [159] [160] [161] or genomic 162, 163 methods. This problem has been addressed by the development of a chemoproteomic technology termed activity-based protein profiling (ABPP) 164, 165 , which uses small-molecule probes to record changes in enzyme activity directly in native biological systems.
An activity-based chemical probe typically contains at least two key features: a reactive group that binds and covalently modifies the active sites of enzymes that share conserved mechanistic and/or structural features; and a reporter tag (for example, a fluorophore or biotin) that enables the detection, enrichment and identification of probe-labelled enzymes (FIG. 3a) .
Activity-based probes have been developed for numerous enzyme classes, including serine hydrolases 166 , cysteine-dependent enzymes [167] [168] [169] , kinases 170 and histone deacetylases 171, 172 . Importantly, ABPP can be applied to any biological sample (cell line, tissue or fluid) and coupled with either gel-or mass spectrometry-based readouts to characterize numerous enzyme activities in parallel 165 .
The most commonly used activity-based probes for serine hydrolases contain a fluorophosphonate-reactive group that covalently reacts with the conserved serine nucleophile in the active site of these enzymes (FIG. 3b) .
A recent global analysis of tissue and cell-line proteomes demonstrated that >80% of mammalian metabolic serine hydrolases react with fluorophosphonate probes 12 . Although it is considerably more challenging to perform an equivalent survey of serine proteases, which typically exist endogenously in their inactive zymogen or inhibitor-bound forms, many of these proteases have also been demonstrated to react with fluorophosphonate probes [173] [174] [175] [176] . ABPP has been applied to discover serine hydrolases that are involved in a range of biological processes, including cancer 148 , nervous system signalling 177 , immune cell function 178 , obesity 179, 180 and infectious diseases 181 . For example, ABPP studies first identified that arylacetamide deacetylase-like 1 (AADACL1; also known as NCEH1) is highly elevated in aggressive cancer cells 182 , where it functions as a 2-acetyl monoalkylglycerol ether (MAGE) hydrolase that controls the levels of the MAGE class of neutral ether lipids 183 . Stable knockdown or chemical inhibition of AADACL1 (with the carbamate inhibitors AS115 or JW480; TABLE 3) in cancer cells reduces the levels of MAGEs and downstream bioactive lysophospholipids, ultimately impairing cancer cell migration and invasion as well as in vivo tumour growth 183, 184 . In addition, monoacylglycerol lipase (MAGL), which cleaves various monoglycerides into free fatty acids and glycerol, was similarly discovered to be highly elevated in aggressive cancer cells and primary tumours 8 , where it controls a free fatty acid network that includes many oncogenic signalling lipids. Overexpression of MAGL in non-aggressive cancer cells promotes their pathogenicity, whereas knockdown or inhibition of MAGL with the selective inhibitor JZL184 (REF. 83) (TABLE 3) impairs tumour growth 8, 185 . In addition to having a potential role in cancer, MAGL is responsible for the hydrolysis and inactivation of the endocannabinoid 2-arachidonoylglycerol, which is an endogenous ligand for the cannabinoid receptors CB1 and CB2. Acute MAGL inhibition with JZL184 results in CB1-dependent hypomotility and antinociception 186, 187 , suggesting that MAGL inhibition could also be a therapeutic strategy for the treatment of pain. MAGL has recently been shown to control the major arachidonate precursor pools for cyclooxygenasemediated biosynthesis of prostaglandins in the brain, through the hydrolysis of 2-arachidonoylglycerol 188 . Importantly, this pathway is distinct from the primarily PLA2-generated arachidonate pools in the gut, and therefore MAGL inhibition may provide a novel way to suppress inflammation in neurodegenerative disorders without causing the gut-associated toxicity observed with cyclooxygenase inhibitors. ABPP had an important role in the discovery of AADACL1 and MAGL as therapeutic targets, and a competitive version of ABPP (described below) was instrumental in the development of AADACL1 and MAGL inhibitors.
Moreover, ABPP analysis has recently shown that retinoblastoma-binding protein 9, which was initially discovered as a protein that could override transforming growth factor-β-mediated antiproliferative signalling 189 , exhibits elevated activity in tumours and promotes anchorage-independent growth and pancreatic carcinogenesis 190 . Preliminary lead inhibitors for retinoblastomabinding protein 9 have been recently discovered using the high-throughput competitive ABPP strategies described below 191, 192 . Further research into other enzymes identified in ABPP studies, many of which remain poorly characterized, should yield insights into their basic biological functions and reveal whether they possess clinical relevance.
Promising new inhibitor discovery strategies Main challenges. There is a notable lack of selective chemical inhibitors for the majority of human serine hydrolases, which is hindering investigations of their physiological roles and relationships to human disease. The dearth of inhibitors is likely to be due to at least three reasons: many enzymes, particularly those that are poorly characterized, lack suitable activity assays to enable compound screening; achieving inhibitor selectivity for one enzyme is difficult among such a large, related protein family; and compound libraries often do not contain tractable starting points for inhibitor optimization. Below, we discuss recently introduced approaches that aim to address these challenges.
Gel-based competitive ABPP. When applied in a competitive format that assays the ability of compounds to block probe labelling of enzymes, ABPP enables the discovery of inhibitors for enzymes independently of their degree of functional annotation 16, 193, 194 . Competitive , then proteomes are prepared and incubated with an activity-based probe. SDS-PAGE separation for fluorophore-tagged probes or mass spectrometry (MS) analysis of biotin-tagged probes enriched with avidin-coupled beads enables the detection and identification, respectively, of the active enzymes in a biological sample. Notably, an enzyme that is the target of an inhibitor will show reduced signals in the inhibitor-treated samples relative to vehicle controls (depicted using an '<' sign on the figure) . LC, liquid chromatography.
ABPP traditionally involves the incubation of a native proteome with a small molecule, followed by labelling with a fluorescent activity-based probe, separation of proteins by SDS-PAGE and quantification of the fluorescence intensity of probe-labelled enzymes relative to a control proteome (this is known as gel-based competitive ABPP;
FIG. 3c) 13, 16 . A complementary mass spectrometry-based platform termed competitive ABPP-multidimensionalprotein identification technology (MudPIT) has been introduced to further enhance the total protein coverage 
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ABPP, activity-based protein profiling. *Electrophiles that covalently react with the serine residues in the active site of the target enzymes are coloured in red.
Fluorescence polarization
A measure of the apparent size of a fluorophore; it is widely used to study molecular interactions. Briefly, a fluorophore excited with plane-polarized light will emit polarized light parallel to the plane of excitation unless it rotates in the excited state.
As the speed of rotational diffusion is inversely proportional to molecular volume, the resulting extent of depolarization gives a relative estimate of the size of the fluorophore.
of these experiments 13, 83 (FIG. 3c) . ABPP-MudPIT experiments require larger quantities of sample and more time than gel-based ABPP and are therefore typically reserved for more in-depth analysis of interesting lead inhibitors. In either gel-based or mass spectrometry-based formats, a key advantage of competitive ABPP is that it permits simultaneous optimization of both the potency and selectivity of inhibitors against numerous related enzymes without requiring protein purification.
Gel-based competitive ABPP screening has enabled the discovery of selective inhibitors for many serine hydrolases (TABLE 3) , including MAGL 83 , abhydrolase domain-containing protein 6 (ABHD6) 12, 13 and FAAH 16, 104 (TABLE 2). Key to the success of these efforts was the iterative optimization of compounds containing mechanismbased electrophiles, including carbamates, ureas and activated ketones. Recently, to expand the number of enzyme-inhibitor interactions evaluated by competitive ABPP, a library of ~150 carbamates was screened against a representative 72-member panel of metabolic serine hydrolases 12 . Lead compounds were identified for numerous serine hydrolases, including currently pursued drug targets (for example, PLA2G7 and FAAH) and uncharacterized enzymes (for example, ABHD11). Two compounds were subsequently optimized to create the first potent, selective and in vivo-active inhibitors for the poorly characterized enzymes ABHD11 (REF. 12 ) and AADACL1 (REFS 12, 184) . Interestingly, this global analysis also identified several unanticipated pharmacological crosspoints within the serine hydrolase class, where two enzymes distantly related by amino acid sequence were found to share inhibitor sensitivity profiles.
Such findings underscore the value of chemopro teomics methods like competitive ABPP that can assess compound selectivity broadly across an entire enzyme class. Some classes of enzymes (for example, the DPPs), however, were not inhibited by any of the tested carbamates, indicating that additional chemotypes may be necessary to successfully target most -if not all -subsets of serine hydrolases. Consistent with this premise, competitive ABPP analysis of a library of triazole ureas recently identified selective inhibitors for enzymes that were insensitive to carbamates, including platelet-activating factor acetylhydrolase 2 and acyl-peptide hydrolase 15 (TABLE 3).
Competitive ABPP was also used to assess the selectivity of the urea-based FAAH inhibitor PF-04457845 before this compound entered clinical trials 14 . Like other ureabased inhibitors of FAAH 108 , PF-04457845 irreversibly inactivates FAAH by carbamylating the serine nucleophile in its active site. Even though there are many irreversible inhibitors currently on the market, the pharma ceutical industry tends to prefer non-covalent, reversible inhibitors largely owing to concerns that irreversible inhibitors will lack specificity for a single protein target 30 . This concern, however, can be directly addressed by competitive ABPP and related chemoproteomics methods 195 ; when these approaches were applied to urea inhibitors of FAAH, such as PF-04457845, the compounds were found to be extremely selective for FAAH relative to serine hydrolases (and the rest of the proteome) 14, 108 . Once such a high degree of selectivity has been established for irreversible inhibitors, their distinctive advantages over reversible inhibitors can be exploited, particularly the fact that they often inactivate their protein targets at very low doses (even when exhibiting suboptimal pharmacokinetic properties) in vivo 30, 195, 196 . Moreover, the enzyme itself serves as a biomarker for compound activity, as in vivo inhibition can be experimentally verified by ABPP of cell, tissue or fluid proteomes from compound-treated animals 83 .
High-throughput screening by competitive ABPP. Competitive ABPP has traditionally been limited by low throughput, as only a few hundred compounds can be reasonably screened by gel-based methods. To overcome this barrier, a high-throughput version of competitive ABPP has recently been introduced in which the interaction between an activity-based probe and an enzyme is monitored by fluorescence polarization 191 (FIG. 4) . The fluorescence polarization-ABPP platform has been applied to numerous enzymes from multiple mechanistic classes 192, 197, 198 , including several serine hydrolases. In one example, PPME1, a serine hydrolase that removes an unusual post-translational carboxymethylation from the C-terminus of protein phosphatase 2A 199 and has been implicated in Alzheimer's disease 200 and cancer 146 , was screened against the US National Institutes of Health (NIH) library of more than 300,000 small molecules 198, 201 . This effort uncovered an aza-β-lactam inhibitor (ABL127; TABLE 3) that selectively and covalently inhibits PPME1 with nanomolar potency. Without requiring any medicinal chemistry optimization, ABL127 showed excellent activity in living cells and in mice, where it selectively inhibited PPME1 relative to other serine hydrolases and decreased the levels of demethylated protein phosphatase 2A. Interestingly, ABL127 originated from an academic contribution to the NIH library from a synthetic chemistry laboratory exploring the substrate scope of a chiral catalyst 202 . ABL127 was contributed to the NIH library without any specific protein target in mind; this underscores the potential of academic chemistry, when paired with high-throughput screening, to serve as a driving force for the discovery of new bioactive chemotypes and chemical probes.
Substrate activity screening. Even though competitive ABPP platforms address several crucial challenges in the discovery of serine hydrolase inhibitors, they still rely on the identification of suitable lead inhibitors from targeted or large-scale chemical libraries. This approach could be enhanced by the discovery of new hydrolasedirected inhibitory chemotypes, as mentioned above. In a complementary strategy, Ellman and colleagues 203 have introduced a technique termed 'substrate activity screening' . This method involves screening a diverse library of N-acyl aminocoumarins, which emit fluorescence when cleaved, to identify initial weakly-binding enzyme substrates. After a substrate is optimized for improved binding, the cleaved bond can then be replaced with a mechanism-based pharmacophore to convert the substrate into an inhibitor. b Substrate activity screening has been successfully applied to both cysteine 203, 204 and serine (chymotrypsin) 205 proteases. As this method requires some intrinsic activity on at least one member of the N-acyl aminocoumarin library, the creation of more structurally diverse screening sets of N-acyl aminocoumarin substrates should increase its success. Enzyme substrates, including those without any intrinsic fluorescence, could also be identified by other methods -for example, by appearing as weak inhibitors in competitive ABPP experiments 192 . These substrates could potentially be converted into effective inhibitors via the introduction of appropriate chemical warheads following the design principles put forth by Ellman and colleagues in the substrate activity screening technique.
Serine traps as 'tethers' for lead discovery. Regardless of their inherent capacity for enzyme selectivity and/ or bioavailability, electrophilic traps can also be used as tethers to enable the initial identification and optimization of lead compound scaffolds that would otherwise bind too weakly for detection. For example, researchers at Merck screened a library of α-keto hetero cyles, a chemotype known to inhibit serine hydrolases 16, 206 , to obtain a starting point for the development of PRCP inhibitors 119 . After carrying out compound optimization, the α-keto heterocyle group was replaced with an isostere to improve its selectivity for PRCP over related enzymes, avoid potential bioavailability liabilities resulting from the ketone moiety, and facilitate derivative synthesis. Similarly, an electrophilic ketone was used in the early-stage development of ximeligatran 44 . A conceptually analogous strategy -called tetheringhas shown promise for the identification of starting points for ligand development for several protein classes 207, 208 , and could also prove to be useful for the discovery of serine hydrolase inhibitors. This strategy involves engineering a cysteine residue into a protein (or using a native cysteine residue, if one exists) to covalently capture weakly-binding disulphide-containing compounds. It should also be noted that the recent discovery of a selective inhibitor of HCV NS3 protease that covalently reacts with a non-catalytic cysteine residue in the enzyme active site suggests that directly targeting native cysteine residues (without removing the tether) could also form the basis of a novel inhibitor discovery strategy 209 .
Engineering of biologics.
Although the inhibition of intracellular serine hydrolases is still the exclusive domain of small molecules, some extracellular serine hydrolases may also be targeted by large macromolecules (such as hirudin and tick anticoagulant peptide). Encouragingly, the engineering of such macromolecular protease inhibitors has already been successful in the discovery and improvement of pharmacological tools 46, 210 . For example, Craik and colleagues 211 used phage display to optimize the Escherichia coli protein ecotin, which naturally inhibits several trypsin-fold proteases, for the selective inhibition of plasma kallikrein. Similarly, Kunitz domain-containing proteins have been modified for the selective blockade of plasma kallikrein 210 and tissue factor-factor VIIa complexes 212 . In addition to natural protein scaffolds with intrinsic protease inhibitor activity, antibodies have been developed to selectively block the activity of certain serine proteases [213] [214] [215] . One advantage afforded by such protein scaffolds is the ability to inhibit regions of the enzyme outside the active site, which are traditionally challenging to target with small molecules 215 .
Conclusions
Serine hydrolases have already yielded targets for marketed drugs that treat an array of human diseases. Given this precedent, it is tantalizing to extrapolate that many additional drug targets may be found among the numerous enzymes from this class that remain poorly characterized. Achieving this goal, however, will require more extensive efforts to elucidate the biochemical and A plate is filled with a purified enzyme before the addition of a compound -an inhibitor (part a) or an inactive compound (part b) -to each well. An activity-based probe is then added to all wells and fluorescence polarization is read after a fixed time interval. The interaction between the probe and enzyme will result in an increase in the fluorescence polarization signal (part b) unless the compound in the well acts as an inhibitor of the enzyme and blocks probe labelling (part a). ABPP, activity-based protein profiling.
physiological roles of serine hydrolases, as well as their relevance in diseases. In this regard, we believe that the development of selective and in vivo-active inhibitors is crucial. Indeed, many serine hydrolases have complex roles in mammalian physiology that cannot easily be modelled in cell culture experiments; for instance, the regulation of the glucagon-like peptide 1 incretin by DPP4 or the termination of cholinergic and endocannabinoid signalling in the nervous system by AChE and FAAH, respectively, are two examples. These pathways, and possibly many other pathways that are regulated by serine hydrolases, require the integrated physiology of an intact animal for their characterization.
So far, in vivo-active inhibitors are available for only a handful of serine hydrolases. Although it might be tempting to prioritize -based on current biological knowledge -enzymes from this class for future inhibitor development efforts, we would urge against this inclination. As Edwards and colleagues 216 have effectively delineated in their article, there appears to be a strong correlation between the volume of research activity (and biological understanding) on a particular protein and the availability of high-quality chemical tools to probe the function of that protein. This type of meta-analysis suggests that the creation of inhibitors often precedes and drives our biological understanding of enzymes, rather than the other way around, and argues for the development of inhibitors for all enzymes, regardless of their current perceived biological and/or therapeutic importance.
Encouragingly, inhibitors emerging from competitive ABPP span the full range of serine hydrolases to include enzymes that are biologically characterized and those that are devoid of functional annotation. Despite having a covalent mechanism of action, many of these inhibitors show remarkable selectivity for their enzyme targets as judged by counterscreening against more than 50 serine hydrolases in proteomes and, in some cases, the use of clickable probes to directly profile reactivity across the entire proteome. Several of the clinically approved drugs targeting serine hydrolases are themselves covalent inhibitors; this suggests that these chemotypes have the potential to yield not only useful probes but also therapeutic agents. More extensive profiling would of course be required to advance ABPP-derived inhibitors from chemical probes to drug candidates. Care must also be taken in the development of covalent inhibitors to ensure that the reactivity of electrophilic groups is tempered enough to enable the development of selective probes.
Continued efforts following the inhibitor discovery strategies described in this Review -particularly highthroughput screening of compound libraries and diversification of mechanism-based electrophiles -show particular promise, in our opinion, to deliver new chemical probes for serine hydrolases. We also believe that further expansion of the NIH small-molecule library with structurally diverse compounds like the aza-β-lactams should provide useful new starting points for probe and drug development, as well as an exciting opportunity for academic synthetic chemists to contribute to biological discovery. Although achieving the ultimate goal of developing a selective and in vivo-active inhibitor for every mammalian serine hydrolase (as well as crucial serine hydrolases in important human pathogens) may seem challenging, we believe that it can be accomplished. The resulting pharmacopoeia would not only power biological discovery but also serve as a starting point for next-generation therapeutics for the improvement of human health.
